key: cord-0811307-somy60o3
authors: Brentville, VA; Vankemmelbeke, M; Metheringham, RL; Symonds, P; Cook, KW; Urbanowicz, R; Tsoleridis, T; Coleman, CM; Chang, K-C; Skinner, A; Dubinina, E; Daniels, I; Shah, S; Dixon, JE; Pockley, AG; Adams, SE; Paston, SJ; Daly, JM; Ball, J; Durrant, LG
title: A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants
date: 2021-06-18
journal: bioRxiv
DOI: 10.1101/2021.06.18.448932
sha: 478b4750d9f685ae99c9e0a045008b53f34f1ce1
doc_id: 811307
cord_uid: somy60o3

The efficacy of vaccines targeting SARS-CoV-2 is becoming apparent now that the mRNA and adenovirus vector vaccines that have been approved for emergency use are showing promise. However, the longevity of the protective immune response and its efficacy against emerging variants remains to be determined. To improve longevity and future protection against variants, we have designed a DNA vaccine encoding both the SARS-CoV-2 spike (S) protein receptor-binding domain (RBD) and its nucleocapsid (N) protein, the latter of which is highly conserved amongst beta coronaviruses. The vaccine elicits strong pro-inflammatory CD4 Th1 and CD8 T-cell responses to both proteins, with these responses being significantly enhanced by fusing the nucleocapsid sequence to a modified Fc domain. We have shown that the vaccine also stimulates high titre antibody responses to RBD which efficiently neutralise in both a pseudotype and live virus neutralisation assay and show cross reactivity with S proteins from the emerging variants Alpha (B.1.1.7) and Beta (B.1.351). This DNA platform can be easily adapted to target variant RBD and N proteins and we show that a vaccine variant encoding the B.1.351 RBD sequence stimulates cross-reactive humoral and T-cell immunity. These data support the translation of this DNA vaccine platform into the clinic, thereby offering a particular advantage for targeting emerging SARS-CoV-2 variants.

The current SARS-CoV-2 pandemic has prompted a global response with researchers from hundreds of institutions across the world developing and testing potential vaccine candidates that can prevent infection and COVID-19 disease. SARS-CoV-2 is known to facilitate host cell entry by targeting the cellular receptor, ACE2 using its densely-glycosylated spike (S) protein. The S protein is a trimeric class I fusion protein which undergoes several structural rearrangements and cleavage events to eventually fuse the viral and host membranes [1, 2] , a process triggered by S1 subunit binding to the host cell receptor ACE2 via its receptor binding domain (RBD). The virus targets the airway epithelial cells, alveolar epithelial cells, vascular endothelial cells and macrophages in the lung, all of which express ACE2 [3, 4] . Viral assembly inside the host cell requires four structural proteins, the S, matrix (M), envelope (E), and nucleocapsid (N) proteins. Homotrimers of the S protein make up the receptor-binding spikes on the viral surface [5, 6] . The N protein contains two domains that each bind the viral genome, packaging it into virions [11] [12] [13] . SARS-CoV-2 has a singlestranded positive sense RNA genome and the coronavirus family have the largest genomes in this category of viruses, encoding RNA processing and editing enzymes which increase the fidelity of replication. However, variation arises through a high rate of homologous recombination. Although SARS-CoV-2 can cause severe symptoms and death in the elderly or clinically vulnerable populations, the fact that approximately 80% of infected individuals present with no symptoms or mild infection [14] suggests that effective immunity can control the infection.

As the S protein has been shown to be the primary target for neutralising antibodies in patients with SARS-CoV-2 [15] , it has been the focus of most vaccine development programmes. Although, the S protein is also a key target for T cell responses, responses have also been detected against the M, E and N proteins and several other non-structural proteins [16] . The currently approved SARS-CoV-2 vaccines and most of those under development predominantly aim to stimulate neutralising antibody responses against the S protein to block the virus binding to ACE2 receptor and entering cells. However, viral evolution has created numerous mutations in the S protein that not only have increased infectivity but have also reduced the efficacy of neutralising antibodies that have been raised to previously encountered viruses [17] [18] [19] [20] . The N protein plays a vital role in viral RNA replication and the formation of new virions and is therefore highly conserved between coronaviruses [4, 21] . It is present in large quantities and can stimulate a strong immune response. Critically, most survivors of SARS-CoV-2 show evidence of T cell and antibody immunity against the N protein [22] , suggesting that it is a target of the natural immune response. Our vaccine design includes the N protein in order to provide broader immunity during the ongoing viral pandemic, a strategy also being considered by other next generation vaccine developers [23] .

We have previously shown that delivery of epitopes from tumour antigens, linked to human immunoglobulin G1 (IgG1) fragment crystallisable (Fc) in a DNA vector, stimulates high avidity CD8 T cell responses that are efficiently recruited into the memory pool [24] [25] [26] . The DNA vector enables direct presentation of the encoded epitopes in antigen presenting cells (APCs) as well as cross presentation of secreted Fc-fused proteins to dendritic cells via high affinity FcγR1 receptor (CD64) binding. This DNA vaccine platform has been successfully used in the clinic as a cancer immunotherapeutic, where it has shown to induce vaccinespecific T-cell responses in patients with melanoma and was compatible with a prime and multiple boosts dosing regimen [27] . Additionally, we have recently described an Fcengineering approach which increases the functional avidity of antibody target binding by enhancing Fc:Fc cooperativity [28] and this modified Fc forms part of our vaccine design.

Herein, we describe the validation of this versatile and rapid to manufacture DNA platform for the generation of a SARS-CoV-2 vaccine targeting both the N protein and the S RBD .

We report that the linkage of the N protein to the modified Fc enhances T cell immunity, and show that the inclusion of this N-modified Fc fusion alongside the RBD antigen in a bivalent DNA vector stimulates strong cellular and humoral immunity to both antigens. High titre antibody responses that exhibited pseudotype neutralisation with a 50% reduction in infective dose (ID 50 ) of >5000 were induced. High frequency CD8 and Th1 CD4 T cell responses to both RBD and N proteins were stimulated. Finally, we demonstrate the induction of variant cross-reactive immune responses and the flexibility of this DNA platform for targeting SARS-CoV-2 variants. Collectively, these results underpin the advancement of this DNA vector encoding RBD and modified Fc-linked N protein into clinical trials.

The backbone of the vaccine plasmids was derived from the FDA regulatory compliant vector backbone of pVAX1 (Invitrogen) for use in humans. All nucleotide sections for insertion were codon optimised for expression in humans and contain a human IgH leader (MDWIWRILFLVGAATGAHS). Codon-optimised nucleotide sections encoding the leader, amino acids (aa) of the S glycoprotein RBD domain 319-541 or 330-525 (GenBank accession number YP_009724390, isolate Wuhan-Hu-1) alone, fused in frame with either the Hinge-CH2-CH3 domain of the human IgG1 Fc constant region (GenBank accession number P01857) or the variant Hinge-CH2-CH3 iV1 (where 23 amino acids (aa) have been replaced with murine IgG3 residues) or attached to a fibritin trimer fold on (GYIPEAPRDGQAYVRKDGEWVLLSTFL) or disulphide bridge motif (CCGGGSG) via a glycine serine linker were synthesised with BamHI and XhoI sites inserted at the 5′ and 3′ends respectively. In the first round of cloning, these sections were inserted into the BamHI/XhoI sites of the pVaxDCIB68 (SCIB1) plasmid as described previously [24, 29] , in direct replacement of the SCIB1 light kappa chain in the first expression cassette to generate intermediate plasmids.

In a second round of cloning codon-optimised nucleotide sections encoding the leader, fulllength nucleoprotein aa 2-419 (Accession number YP_009724397) alone or fused in frame with the Hinge-CH2-CH3 domain of the human IgG1 constant domain or the variant Hinge-CH2-CH3iV1 were synthesised and flanked with HindIII/PstI. The heavy chain was excised using HindIII/PstI from the intermediate vectors generated from the first round and replaced with the N protein sections in the second expression cassette alongside the appropriate S section ( Figure 1A ). The sequences of both chains within each expression cassette of the pVaxDC vectors were confirmed by the dideoxy chain termination method [30] .

The plasmid pCMV3-2019-nCoV-Spike (S1+S2)-long encodes full-length spike from SARS- sodium azide added to a final concentration of 0.2% (w/v). Cell pellets were stored at -80°C.

Cell lysates (intracellular RBD and N protein) were generated by processing the cell pellets in a suitable volume of RIPA buffer (Sigma Aldrich R0278) according to the manufacturer's recommendations.

Sandwich ELISA for detection of secreted and intracellular RBD and N protein Commercial kits/antibody pairs were used in both cases. N protein was detected using the SARS-CoV-2 NP ELISA kit from Bioss, (cat# BSKV0001) according to the supplier's instructions. Quantitation relied on the standard curve generated using the NP standard supplied with the kit. RBD was detected using a sandwich ELISA consisting of a capture antibody (SARS-CoV-2 S neutralising mouse monoclonal antibody (mAb) Sino Biological, 40591-MM43) combined with an HRPO-labelled detection antibody from the SARS-CoV-2 spike RBD Antibody Pair (Epigentek A73682). Capture antibody was coated at 200 ng/well and detection antibody was used at a dilution of 1:1000.

Peptides were selected based on immune epitope database (IEDB) (http://www.iedb.org/) binding predictions [31] and from reports in the literature. Peptides (Table S1 ) were synthesised at >90% purity (GenScript), stored lyophilised at -80°C and then reconstituted in phosphate buffered saline (PBS) on day of use. SARS-CoV-2 RBD and N protein peptide pools were purchased from JPT Peptide Technologies and GenScript, respectively. SARS-CoV-2 N and S1 proteins were obtained from Genscript and Sino Biological. (v/v) CO 2 . Spots were counted using an automated plate reader (Cellular Technologies Ltd).

Splenocytes (5x10 6 /mL) were incubated with 5 µg/mL synthetic peptide or 0.5 µg/mL whole recombinant protein for 7 days. Cells were washed, plated at 5x10 6 /ml and stimulated for 8-12 hr with medium alone, 0.25 μ g/mL CD3 mAb (Thermofisher) as a positive control, 5 μ g/ml synthetic peptide or 1 μ g/mL peptide pool. Cells were incubated at 37°C for 8 hr with

Brefeldin A (BD Biosciences) and Monensin (Thermofisher) being added for the last 7 hr of incubation. After 8 hr incubation, cells were held at 4°C until staining. Cells were then washed and stained with APC efluor780 conjugated anti-mouse CD4 and Viogreen TM conjugated anti-mouse CD8 mAbs. Cells were subsequently washed, fixed and permeabilised using intracellular fixation/permeabilisation buffers (ThermoFisher).

Intracellular antibody staining was performed in permeabilisation buffer for 30 min before washing and fixing. Stained samples were analysed using a Milteny Biotech MACSQuant TM 10 flow cytometer. Full details of the mAbs used are provided in Table S2 .

ELISA for N and S1 specific antibodies Blood collected from mice was allowed to clot for at least 30 min at room temperature, centrifuged at 1000g for 10 min and serum collected. Serum from naïve mice was used as a control. Sera were diluted in 2% (w/v) bovine serum albumin in PBS (BSA-PBS) and

incubated for 1 hr at room temperature (RT) in coated (S1 antigen, GenScript #Z03501 or Sino Biological and N-protein, GenScript #Z03488, both at 200 ng/well) and blocked ELISA plates. Antibody binding to S1 antigen was detected using a three-step approach consisting of anti-mouse Fc biotin (Sigma Aldrich B7401) followed by streptavidin-HRPO (Life Technologies SA1007) and finally TMB (3,3´, 5, 5´-tetramethylbenzidine) Core+ reagent (Bio-Rad BUF062C) for development. Antibody binding to N protein was detected using conventional two-step ELISA with an HRPO-conjugated anti-mouse Fc antibody (Sigma Aldrich A9309). All assays included a standard curve of mouse neutralising S1 antibody and mouse anti-N antibody (Sino Biological). Standard curves were used to extrapolate the amount (µg/mL) of specific immunoglobulin (Ig) in the sera samples.

Pseudotype neutralisation assay SARS-CoV-2 S protein plasmids were generated and cloned, and pseudoparticles generated as previously described [32, 33] . Briefly, 1. inhibition) as constraints to assist curve fitting.

Live virus neutralisation assay SARS-CoV-2 infectious virus (CVR-GLA-1) was obtained from the National was obtained from the Centre For AIDS Reagents, NIBSC, UK.

Live virus neutralisation assays were performed using method previously described [34] , except that 790 TCID 50 /ml of the SARS-CoV-2 virus was added to each serum dilution.

Additionally, for some experiments, the sera were diluted down to 1:81,920.

A V-PLEX COVID-19 ACE2 neutralisation kit from Meso Scale Diagnostics LLC was used to investigate the ability of vaccine-elicited antibodies to block the binding of ACE2 to RBD or whole S proteins. V-plex SARS-CoV-2 Panel 7 multispot plates containing S1 RBD and whole S proteins from Lineage A (originally identified in Wuhan) and variant (B1. 

Spike RBD and N protein DNA sequences were obtained from the Lineage A SARS-CoV-2 variant and engineered alongside N terminal human IgH leader sequences into the pVAX1 vector backbone. Short (aa330-525) or long (aa319-541) S protein RBD sequences were fused in frame with human IgG1 Fc constant region, a fibritin timer domain or disulphide bridge motif ( Figure 1A ). N protein sequences were added alongside the S protein RBD sequences, alone or fused in frame with human IgG1 Fc (Fc) constant region or a modified human IgG1 Fc (Fc iV1) constant region ( Figure 1A ).

Expression of both N protein and RBD from DNA constructs was assessed by transfection of (Table   S1) .

A high frequency of T cells specific to the N protein was detected in mice immunised with DNA constructs containing the N protein linked to modified Fc (iV1) when compared to Figure 3C ), these peptides have been described as potential HLA-A2 epitopes in human studies [35, 36] . To confirm these to be CD8 peptides, the T cell responses were assessed in the presence of CD4 or CD8 blocking antibodies ( Figure 3D ). The presence of the CD8 blocking antibody totally abrogated both responses (p<0.0001) whereas the CD4 blocking antibody had little effect, thus confirming that these were CD8 responses in HLA-A2 transgenic mice.

To characterise the T cell responses to the longer peptides which have the potential to contain both CD8 and CD4 epitopes, BALB/c mice were immunised with DNA constructs expressing RBD alongside N linked to modified Fc (iV1) and T cell responses to the N 80-100 and RBD 505-524 peptides monitored by IFNγ ELISpot assay in the presence of CD4 or CD8 blocking antibodies. A strong T cell response to the N 80-100 peptide was observed and this was efficiently blocked by the CD4 antibody (p=0.0009) but not the CD8 antibody,

implying the presence of a CD4 epitope within this peptide sequence (Figure 3Eii ). Although a strong T cell response to the RBD 505-524 peptide was observed this was not significantly inhibited by either the CD4 or CD8 blocking antibodies, suggesting that this peptide sequence stimulates both CD4 and CD8 responses (Figure 3Ei ). responses to the N protein which is consistent with the ELISpot data ( Figure 4A ). There was no evidence of any IL-10 responses.

Responses of splenocytes from the BALB/c mice in the ELISpot and intracellular cytokine analysis to the RBD peptide pool and the RBD 505-524 peptide were anticipated to be both CD4 and CD8 mediated. To confirm this, splenocytes from immunised BALB/c mice were expanded in vitro with RBD 505-524 peptide and examined by intracellular cytokine staining.

The response to the RBD 505-524 peptide was predominantly CD8 cells making both IFNγ and TNFα but no IL-10 ( Figure 4B ). However, a small response in the CD4 population was also observed thus providing evidence that this peptide contains both CD4 and CD8 epitopes and confirming both CD4 and CD8 RBD specific responses are generated by this vaccine construct.

In addition to the responses in the BALB/c model, responses to the N and RBD proteins were further characterised in C57Bl/6 mice. For this, splenocytes from immunised C57Bl/6 mice were also expanded in vitro with S1 or N proteins and analysed for specific responses by intracellular cytokine staining. Figure 4C shows Humoral responses were evaluated in sera from immunised BALB/c mice immunised with constructs containing the RBD monomer, whole S, trimer or monomer linked to Fc and analysed for reactivity to SARS-CoV-2 S1 protein by ELISA. (Figure 5Ai and ii). Vaccination induced potent antibody responses to the S1 protein which were detectable in sera from all constructs at up to 1 in 100,000 dilution. Constructs containing the RBD monomer and RBD linked to Fc showed the highest EC 50 and quantity of Ig with approximately 50 µg/mL anti-S1

Ig being detected.

The generation of a potent antibody response capable of inhibiting the binding of the S protein to ACE2 receptor and subsequent viral infection is vital for an effective SARS-CoV-2

vaccine. The ability of sera from mice immunised with the DNA constructs containing RBD monomer, trimer or monomer linked to Fc to prevent viral infection was therefore tested in a pseudotype neutralisation assay. For this, sera from mice immunised with the RBD monomer showed higher neutralisation IC 50 values (Figure 5Bi -ii) with 50% neutralisation at serum dilutions of greater than 1in 5000, higher than that seen with the NIBSC 20/136 international antibody standard. Sera from mice immunised with the RBD monomer DNA construct showed higher IC 50 neutralisation values compared to that from mice immunised with the DNA expressing the whole S ( Figure 5C ). This is also evident from the differing antibody levels shown in Figure 5Aii where the RBD monomer generated high EC 50 values when compared to the construct expressing full-length S antigen.

Sera were also analysed for reactivity to SARS-CoV-2 N protein by ELISA. Lower antibody responses were seen to the N protein than to the RD, with similar EC 50 values obtained for all constructs irrespective of whether the N protein was fused to Fc or not ( Figure 5D ).

Emerging SARS-CoV-2 variants are a major cause for concern as they have the potential for greater infectivity and increased disease severity. As variants of SARS-CoV-2 have the potential to impact the efficacy of the current vaccines approved for emergency use that were generated using the original Lineage A virus, there remains doubt about the effectiveness of current vaccines based on this isolate against these new variants. We therefore examined the ability of sera from BALB/c mice immunised with the DNA vaccine expressing RBD alongside N linked to modified Fc (iV1) (also known as SN15) for reactivity to the Lineage A SARS-CoV-2 S1 protein as well S1 proteins incorporating the mutations seen in the B.1.1.7 (Alpha) and B.1.351 (Beta) variants by ELISA. Vaccination induced a potent antibody response with reactivity to all the S1 proteins detectable in sera at up to a 1 in 100,000 dilution ( Figure 6A ). However, in line with other reports, we also observed a significant (p<0.0001) reduction in reactivity to the B.1.351 (Beta) variant S1 protein compared to the Lineage A protein, whereas reactivity to the B.1.1.7 (Alpha) variant S1

protein was not significantly reduced.

One of the most concerning variants of concern (VoC) currently in circulation is B. analysed for reactivity to the original Lineage A SARS-CoV-2 S1 protein as well S1 protein incorporating the mutations seen in the B.1.351 (Beta) variant by ELISA. Substantial antibody responses were observed to the protein variants up to 1 in 100,000 dilution ( Figure   6B ). As noted above, sera raised against the original Lineage A vaccine exhibited a decrease in reactivity to the B.1.351 (Beta) variant S1 protein compared to the Lineage A S1

protein with the EC 50 suggesting SARS-CoV-2 variants have little impact on the T cell responses induced [40] . A strong T cell response is not only essential for the generation of humoral immunity in coronavirus infection [41] but has also been shown to persist over time and is therefore likely to be important for long term protection [22, 42] . Grifoni et al. have indeed shown the importance of both T cell and humoral immunity to S and N proteins for SARS-CoV-2 protection [16] . Evidence from SARS-CoV demonstrates the persistence of T cell responses to both S and N proteins up to 11 years post infection [42] . In addition, studies in mouse models of SARS-CoV have shown that memory CD8 T cells provide efficient protection from SARS-CoV infection [43] . Therefore, to be most effective, immunity stimulated by vaccination will likely need to comprise of both potent virus-specific CD8 and CD4 T cell responses as well as neutralising antibody responses. Several reports using murine models indicate that a strong Th1 response alongside virus specific CD8 response and virus specific neutralising antibodies are necessary for successful control of SARS-CoV and MERS [44, 45] . Although it is too early to determine the full extent of longevity of the T-cell responses for SARS-CoV-2 in humans, infection-specific memory T cells have been detected in convalescent patients and responses can be detected up to 18 weeks after infection.

Interestingly the responses to S antigen in convalescent patients appear superior to those detected in individuals vaccinated with the current approved vaccines [46] which is consistent with our unpublished data analysing responses to SARS-CoV-2 in humans.

convalescent patients were more prevalent to antigens that are not subject to mutational variation such as the N protein [47, 48] . In further support of these data, the study by Le

Bert et al demonstrated that N protein specific T cell responses in patients who were infected with SARS-Co-V were more likely to cross react with homologous SARS-CoV-2 peptides than those from NSP7 and NSP13 [22] . This supports the rationale for targeting of both S and N proteins in vaccine design such as the strategy described in this study to induce both T cell and antibody mediated immunity.

Herein, we have achieved simultaneous production of strong neutralising antibody titres as well as potent CD8 and CD4 T cell responses to epitopes from both SARS-CoV-2 S and N proteins. The RBD monomer elicited the strongest neutralising antibody responses with ID 50 titres of >5000. In this study, these titres were higher than those elicited by a DNA vaccine encoding whole S protein, which was also reflected in the ACE2 binding inhibition assay, suggesting that vaccination with RBD may elicit higher neutralising antibody titres than vaccination with the complete S antigen. These data compare favourably with other studies in which the whole S protein or an RBD trimer have been used to produce vaccine candidates that generate potent neutralising antibodies [23, [49] [50] [51] [52] . Indeed, it has been demonstrated that the majority of the neutralising antibodies to S protein target the RBD, supporting the inclusion of just the RBD sequence in this bivalent vaccine [53] .

In addition to strong RBD specific antibody responses the induction of antibody responses to the N protein were also detected. Although, these are likely to be non-neutralising antibodies, they often have the ability to clear viral infections [54] [55] [56] . using a Ad5 vectored delivery platform [23, 59] . This delivers a modified S protein to promote surface expression and a modified N protein to enhance MHCI and II presentation, resulting in the generation of both N and S specific T cell and neutralising antibody responses in preclinical studies [23] . In humans, T cell responses generated from a single dose of vaccine are of similar frequency to those seen in previously infected patients, although no data on antibody responses are reported [59] .

The emergence of new SARS-CoV-2 variants has highlighted the importance of generating a vaccine mediated response that is effective against the variants as well as the original strain.

Mutations in the S protein have been shown to reduce the recognition by antibodies, thereby allowing the virus to escape antibody neutralising effects and increase the transmissibility, infection rate and disease severity [19, 20, 60, 61] . Sera from immunised mice analysed for anti-S1 (A) or anti-N (D) antibodies by ELISA. Data presented shows absorbance readings with sera titrations (i) and as total µg/mL specific IgG (ii) EC 50 values were calculated and the quantity of Ig in the sera was estimated from the OD value at a 1 in 3000 serum dilution using the standard curve of commercial murine S1 or N antibody.

Sera from BALB/c mice immunised with constructs containing the RBD monomer, trimer or monomer linked to Fc (B), C57Bl/6 mice immunised with construct containing the RBD monomer or whole S protein (C) and the NIBSC 20/136 standard were assessed for neutralisation at increasing sera dilutions (i) and ID 50 values (ii). 

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex

Structure, Function, and Evolution of Coronavirus Spike Proteins

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Architecture of the SARS coronavirus prefusion spike

Assembly of coronavirus spike protein into trimers and its role in epitope expression

Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins

A structural analysis of M protein in coronavirus assembly and morphology

A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo

Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis

Modular organization of SARS coronavirus nucleocapsid protein

Coronaviruses: an overview of their replication and pathogenesis

Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Increased infections, but not viral burden, with a new SARS-CoV-2 variant

Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+

Neutralizing Antibody Responses. bioRxiv

Antibodies designed as effective cancer vaccines

DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells

High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial

Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

DNA sequencing with chain-terminating inhibitors

Immune epitope database analysis resource (IEDB-AR)

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease. medRxiv

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses

Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+)

T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv : the preprint server for biology

SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection

Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

Immunogenicity of a DNA vaccine candidate for COVID-19

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus

A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus

Non-Neutralizing Antibodies Directed against HIV and Their Functions. Front Immunol

Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity

Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. bioRxiv

Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection

Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2. medRxiv

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera